GO
简体中文

Who We Are

BeyondSpring is a Global, Clinical-Stage
Bio-pharmaceutical Company

Developing Innovative Immuno-Oncology Cancer Therapies with a Robust Pipeline from Internal Development and from Collaboration with University of Washington in De Novo Drug Discovery Using a Ubiquitination Platform.

Detail



Development

Pipeline

We have a robust drug development pipeline at various clinical and pre-clinical stages.

Read More
NewsMedia

BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update

Detail

BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019

Detail

BeyondSpring's Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting

Detail

BeyondSpring's Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin's Mechanism of Action for CIN Accepted at American Society of Hematology's 2019 Annual Meeting

Detail

BeyondSpring's Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

Detail

BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

Detail

BeyondSpring Announces Pricing of Ordinary Shares

Detail

BeyondSpring Announces Proposed Public Offering of Ordinary Shares

Detail

BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia

Detail

BeyondSpring's Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors

Detail

Cell Journals Publishes BeyondSpring's New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation

Detail

© BeyondSpring Inc. All Rights Reserved.